<DOC>
	<DOCNO>NCT02090556</DOCNO>
	<brief_summary>The purpose study estimate retention rate Abatacept SC 24 month routine clinical practice , rheumatoid arthritis patient , country involve study . The purpose UK substudy explore whether integrate self-assessment routine care could maintain tight control ( inflammation/disease activity ) potentially low cost result improved health outcome cost-effectiveness .</brief_summary>
	<brief_title>Long-term Experience With Abatacept SC Routine Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Patients ≥18 year old treatment initiation Patients diagnose establish moderate severe active RA per 1987 ACR criteria/2010 American College Rheumatology ( ACR ) /European League Against Rheumatism ( EULAR ) Rheumatoid Arthritis Classification Criteria Patients naïve Abatacept IV physician 's discretion initiate Abatacept SC . In country require ( e.g . Germany Spain ) , patient naïve Abatacept IV physician 's discretion initiate Abatacept SC least 1 month prior enrollment visit 6 month baseline disease characteristic data available For Spanish pharmacogenomic substudy : Caucasian patient European ancestry Patient collection blood sample initiation abatacept possible available ( blood sample take routine practice study enrolment ) Patient agree participate substudy provide specific sign Pharmacogenomic Blood RNA inform consent In UK , ART substudy propose patient enrol ASCORE amendment approval application date Patients currently include interventional clinical trial RA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>